Pharmacology of dementia.
The authors discuss cerebral vasodilators, cerebral metabolic enhancers, nootropics, opioid antagonists, psychostimulants, cholinergic agents, and neuropeptides. Their efficacy in the treatment of dementing illnesses is evaluated.
Klawans
H L
HL
Genovese
N
N
D015761:4-Aminopyridine; D000109:Acetylcholine / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D000368:Aged; D000631:Aminopyridines / Q000494:pharmacology; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D009257:Nafronyl / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D009419:Nerve Tissue Proteins / Q000627:therapeutic use; D010277:Parasympathomimetics / Q000627:therapeutic use; D010433:Pentylenetetrazole / Q000627:therapeutic use; D010830:Physostigmine / Q000494:pharmacology; D010889:Piracetam / Q000494:pharmacology; D011342:Procainamide / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D014667:Vasopressins / Q000627:therapeutic use
D000631:Aminopyridines; D000697:Central Nervous System Stimulants; D009292:Narcotic Antagonists; D009419:Nerve Tissue Proteins; D010277:Parasympathomimetics; D014665:Vasodilator Agents; D014667:Vasopressins; D009257:Nafronyl; D007980:Levodopa; D000255:Adenosine Triphosphate; D010830:Physostigmine; D015761:4-Aminopyridine; D011342:Procainamide; D000109:Acetylcholine; D010433:Pentylenetetrazole; D010889:Piracetam